Literature DB >> 15494875

Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama.

Raymond G Watts1.   

Abstract

Childhood idiopathic thrombocytopenic purpura (ITP) is a common disorder. However, single-institution, long-term, natural history data are limited. The objective of this paper is to review presenting features, response to therapy, and natural history of ITP treated at a single pediatric academic medical center. A retrospective chart review was made for all children (ages birth-18 years) diagnosed with ITP (ICD 287.3) and treated at the Childrens Hospital of Alabama/University of Alabama at Birmingham between 1993 and 2003. Four hundred nine patients were identified (49% male, 51% female; mean age: 5.85 years; range: 1 month-17 years). There was no seasonal variation of presentation. The mean platelet count was 19k (0-120k). Bone marrow aspiration (BMA) was performed in 72% but altered the diagnosis or therapy in no patient. Treatment consisted of corticosteroids in 256 (92% response), intravenous immunoglobulin (IVIG) in 125 (87% response), Win-Rho D in 58 (91% response), and no therapy in 71 (100% response). Response was defined as increase in platelet count to > 50k. There was no difference in response to any therapy. No patients died. One patient presented with a CNS hemorrhage at presentation, responded to therapy, and survived. Twenty-three of 409 patients (6%) experienced clinical bleeding requiring hospitalization or blood transfusion. Chronic ITP (persistence > 6 months) was noted in 99 patients (24%). Chronic patients presented at an older age (7.8 vs 5.2 years for acute only, p<0.001), and with higher platelet counts (27k vs 17k, p<0.001). The risk of chronic ITP was partially predicted by presenting platelet count > 50k and age > 10 years, or both; 50% of patients presenting with these features developed chronic ITP vs 24% overall rate. Splenectomy was curative in 30/31 (97%) patients. There was no postsplenectomy sepsis. Of 99 patients with chronic ITP, 25 responded to splenectomy, 37 resolved at a mean of 20.3 months after diagnosis (7-96 months), 36 had persistent mild thrombocytopenia (50k-125k), and 1 failed to respond to any treatment including splenectomy. Overall, 91% of cases resolved with therapy or observation. ITP is a common pediatric disease presenting at any age with low morbidity and mortality. Most cases can be managed by pediatricians without hematology referral. Several equally successful therapeutic options exist. Chronic cases present at an older age with higher platelet counts. Up to 50% of cases of chronic ITP will resolve with ongoing follow-up. The overall prognosis in childhood ITP is excellent.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15494875     DOI: 10.1177/000992280404300802

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  16 in total

1.  Seasonal variation of immune thrombocytopenic purpura related hospitalizations among adults in the USA: analysis of the nationwide inpatient sample database.

Authors:  Smith Giri; Ranjan Pathak; Madan R Aryal; Paras Karmacharya; Vijaya R Bhatt; Mike G Martin
Journal:  Ther Adv Hematol       Date:  2015-08

2.  Initial Lymphocyte Count as Prognostic Indicator for Childhood Immune Thrombocytopenia.

Authors:  Sinan Akbayram; Kamuran Karaman; Murat Dogan; Lokman Ustyol; Mesut Garipardic; Ahmet Faik Oner
Journal:  Indian J Hematol Blood Transfus       Date:  2016-03-08       Impact factor: 0.900

3.  Contemporary pediatric splenectomy: continuing controversies.

Authors:  James H Wood; David A Partrick; Taru Hays; Angela Sauaia; Frederick M Karrer; Moritz M Ziegler
Journal:  Pediatr Surg Int       Date:  2011-05-28       Impact factor: 1.827

4.  Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms.

Authors:  David E Schmidt; Katja M J Heitink-Pollé; Annemieke G Laarhoven; Marrie C A Bruin; Barbera Veldhuisen; Sietse Q Nagelkerke; Taco W Kuijpers; Leendert Porcelijn; C Ellen van der Schoot; Gestur Vidarsson; Masja de Haas
Journal:  Blood Adv       Date:  2019-07-09

5.  Association between drug and vaccine use and acute immune thrombocytopenia in childhood: a case-control study in Italy.

Authors:  Federica Bertuola; Carla Morando; Francesca Menniti-Ippolito; Roberto Da Cas; Annalisa Capuano; Giorgio Perilongo; Liviana Da Dalt
Journal:  Drug Saf       Date:  2010-01-01       Impact factor: 5.606

6.  Immune thrombocytopenic purpura might be an early hematologic manifestation of undiagnosed human immunodeficiency virus infection.

Authors:  Shih-Wei Lai; Hsien-Feng Lin; Cheng-Li Lin; Kuan-Fu Liao
Journal:  Intern Emerg Med       Date:  2016-08-25       Impact factor: 3.397

7.  Identification of predictive factors for response to intravenous immunoglobulin treatment in children with immune thrombocytopenia.

Authors:  Yoshihito Morimoto; Nao Yoshida; Nozomu Kawashima; Kimikazu Matsumoto; Koji Kato
Journal:  Int J Hematol       Date:  2014-02-27       Impact factor: 2.490

8.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

9.  Outcomes in Mild to Moderate Isolated Thrombocytopenia.

Authors:  Charles Schlappi; Varsha Kulkarni; Prasannalaxmi Palabindela; Christina Bemrich-Stolz; Thomas Howard; Lee Hilliard; Jeffrey Lebensburger
Journal:  Pediatrics       Date:  2018-06-11       Impact factor: 7.124

10.  Identification and characterization of anti-platelet antibodies in idiopathic thrombocytopenic purpura patients.

Authors:  N Aghabeigi; N Lindsey; A Zamani; B Shishaeyan
Journal:  Iran J Public Health       Date:  2012-02-29       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.